{
    "nct_id": "NCT05273307",
    "official_title": "Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy: A Double-blinded, Placebo-controlled, Randomized Phase III Trial",
    "inclusion_criteria": "1. Participants must have documentation of histologically or cytologically confirmed head and neck cancer diagnosis including primary tumors of the following sites: oropharynx, nasopharynx, oral cavity, nasal cavity, paranasal sinus, salivary gland, unknown primary origin in the head and neck, or cutaneous squamous cell carcinoma having had a surgery including neck dissection.\n2. Treatment plan includes curative-intent (including post-operative) radiation therapy with or without concurrent chemotherapy\n3. Age >=18 years at screening visit.\n4. Eastern Cooperative Oncology Group (ECOG) performance status <= 2 (Karnofsky >= 60%)\n5. Ability to understand a written informed consent document, and the willingness to sign it\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patient-reported pre-existing dysgeusia prior to beginning radiation therapy.\n2. Receiving nutrition through tube feeds or intravenously prior to beginning radiation therapy.\n3. Inability to complete patient-reported outcomes (PROs) and quality of life questionnaires in English.\n4. Known allergy to berries.",
    "miscellaneous_criteria": ""
}